IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Portfolio Diversification to Investors

FomoAnxiety · 2026-03-10T21:59:15+00:00

The essay explores the diverse healthcare sector as a means for investors to diversify their portfolios, highlighting various healthcare ETFs focused on medical devices, pharmaceuticals, and biotechnology.

FomoAnxiety

2026-03-10 21:59:15

Abstract generation in progress

Healthcare is a diverse sector that can provide investors with portfolio diversification.

Claim 70% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

Within healthcare there are pharmaceutical companies that make medications; medical device firms that develop products ranging from artificial hearts and pacemakers to hearing aids; and biotechnology concerns that are involved in new technologies such as genomics.

Healthcare exchange-traded funds (ETFs) that focus on specific sectors of the healthcare industry are a great way to boost an investment portfolio, especially funds that are geared towards new treatments and medicines.

Top Specialty ETFs

Some great specialty ETFs for investors to consider include the iShares U.S. Medical Devices ETF IHI -1.62% ▼ , which holds stocks of leading medical device companies such as Boston Scientific BSX -2.70% ▼ , Intuitive Surgical ISRG -1.56% ▼ and Medtronic MDT -1.59% ▼ .

There’s also the iShares U.S. Pharmaceuticals ETF IHE +0.11% ▲ that owns stocks of leading pharma concerns such as Eli Lilly & Co. LLY -0.70% ▼ and Merck & Co. MRK -0.02% ▼ . The ARK Genomic Revolution ETF ARKG -3.05% ▼ invests in companies developing new therapies, such as CRISPR Therapeutics CRSP -10.17% ▼ and Natera NTRA -3.06% ▼ . Below is a chart comparing these three ETFs.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.